Evidence map›Paper›PMID 39131331›Full record

ArticlebioRxiv : the preprint server for biology2024

Neutralization activity in chronic HIV infection is characterized by a distinct programming of follicular helper CD4 T cells.

Eirini Moysi, Ashish A Sharma, Sijy O'Dell, Spiros Georgakis, Perla Mariana Del Rio Estrada, Fernanda Torres-Ruiz, Mauricio González Navarro, Yara Andrea Luna Villalobos, Santiago Avila Rios, Gustavo Reyes-Teran and 14 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors.

Eirini MoysiTissue Analysis Core, Immunology Laboratory, Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA.
Ashish A SharmaPathology Advanced Translational Research Unit, Department of Pathology, Emory University School of Medicine, Atlanta, GA, USA.
Sijy O'DellVirology Laboratory, Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA.
Spiros GeorgakisDepartment of Laboratory Medicine and Pathology, Institute of Pathology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Perla Mariana Del Rio EstradaPathology Advanced Translational Research Unit, Department of Pathology, Emory University School of Medicine, Atlanta, GA, USA.
Fernanda Torres-RuizCentro de Investigación en Enfermedades Infecciosas, Instituto Nacional de Enfermedades Respiratorias "Ismael Cosío Villegas", Mexico City, Mexico.
Mauricio González NavarroCentro de Investigación en Enfermedades Infecciosas, Instituto Nacional de Enfermedades Respiratorias "Ismael Cosío Villegas", Mexico City, Mexico, Subdireccion de Otorrinolaringologia, Instituto Nacional de Rehabilitación "Luis Guillermo Ibarra Ibarra".
Yara Andrea Luna VillalobosCentro de Investigación en Enfermedades Infecciosas, Instituto Nacional de Enfermedades Respiratorias "Ismael Cosío Villegas", Mexico City, Mexico.
Santiago Avila RiosCentro de Investigación en Enfermedades Infecciosas, Instituto Nacional de Enfermedades Respiratorias "Ismael Cosío Villegas", Mexico City, Mexico.
Gustavo Reyes-TeranInstitutos Nacionales de Salud y Hospitales de Alta Especialidad, Secretaría de Salud de México, Mexico City, Mexico.
Margaret H BeddallImmunoTechnology Section, Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA.
Sung-Hee KoVirus Persistence and Dynamics Section, Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA.
Frida BelinkyVirus Persistence and Dynamics Section, Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA.
Michail OrfanakisDepartment of Laboratory Medicine and Pathology, Institute of Pathology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Laurence de LevalDepartment of Laboratory Medicine and Pathology, Institute of Pathology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Ana B EnriquezPathology Advanced Translational Research Unit, Department of Pathology, Emory University School of Medicine, Atlanta, GA, USA.
Clarisa M BucknerLaboratory of Immunoregulation, NIAID, NIH, Bethesda, MD, USA.
Susan MoirLaboratory of Immunoregulation, NIAID, NIH, Bethesda, MD, USA.
Nicole Doria-RoseVirology Laboratory, Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA.
Eli BoritzVirus Persistence and Dynamics Section, Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA.
John R MascolaVirology Laboratory, Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA.
Rafick-Pierre SekalyPathology Advanced Translational Research Unit, Department of Pathology, Emory University School of Medicine, Atlanta, GA, USA.
Richard A KoupTissue Analysis Core, Immunology Laboratory, Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA.
Constantinos PetrovasTissue Analysis Core, Immunology Laboratory, Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA.

Funding

Reversing Immune Dysfunction for HIV-1 EradicationUM1AI164561 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI SUMIT K CHANDA, Paula M Cannon · 2021 to 2026
$30.0M
High-throughput, single-molecule sequence analysis of virus populations in vivoZIAAI005156 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI BORITZ, ELI · 2020 to 2025
$4.4M
NIAID NIH HHS UM1 AI164561
6 · The paper itself

Abstract

A subset of people living with HIV (PLWH) can produce broadly neutralizing antibodies (bNAbs) against HIV, but the lymph node (LN) dynamics that promote the generation of these antibodies are poorly understood. Here, we explored LN-associated histological, immunological, and virological mechanisms of bNAb generation in a cohort of anti-retroviral therapy (ART)-naïve PLWH. We found that participants who produce bNAbs, termed neutralizers, have a superior LN-associated B cell follicle architecture compared with PLWH who do not. The latter was associated with a significantly higher

Indexed as

broadly neutralizing antibodiesHIVlymph nodeTFH

Identifiers

PMID39131331
PMCPMC11312598

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.